Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.40 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.40 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALPG | P10696 | 2/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2647561 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL20262982 | 0.83 | ALPG (0.46) | KMT2AMEN1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL2455030 | 0.82 | GAA (0.42) | KMT2AMEN1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL5656069 | 0.82 | ALDH1A1 (0.44) | KMT2AALDH1A1HTTKCNH2ALPG | |
| SCHEMBL464450 | 0.80 | — | — | |
| SCHEMBL8026054 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL859695 | 0.79 | KMT2A (0.42) | KMT2AMEN1ALDH1A1HTTCYP1A2 | |
| Hydrochloric Acid SCHEMBL1366290 | 0.79 | KMT2A (0.42) | KMT2AMEN1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL23044738 | 0.79 | ALPG (0.44) | KMT2AMEN1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL5655366 | 0.79 | ALDH1A1 (0.59) | KMT2AALDH1A1HTTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888356-B2 | Antibiotics containing borinic acid complexes and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| CN-101928295-A | Antibiotics containing borinic acid complexes and methods of use | ANACOR PHARMACEUTICALS INC | 2010-12-29 | — | — | CN | disclosed |
| US-7652000-B2 | Boron-containing compounds and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-2044091-A2 | COMPOUNDS FOR THE TREATMENT OF PERIODONTAL DISEASE | Anacor Pharmaceuticals, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20080293675-A1 | ANTIBIOTICS CONTAINING BORINIC ACID COMPLEXES AND METHODS OF USE | ANACOR PHARMACEUTCALS INC. (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1980564-A1 | Antibiotics containing borinic acid complexes and methods of use | Anacor Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7393856-B2 | Anti-viral uses of borinic acid complexes | ANACOR PHARMACEUTICALS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7390806-B2 | Antibiotics containing borinic acid complexes and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080146803-A1 | ANTIBIOTICS CONTAINING BORINIC ACID COMPLEXES AND METHODS OF USE | ANACOR PHARMACEUTICALS, INC. | 2008-06-19 | — | — | US | disclosed |
| EP-1581500-A4 | ANTIBIOTICS CONTAINING BORINIC ACID COMPLEXES AND METHODS OF USE | ANACOR PHARMACEUTICALS INC (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20060019927-A1 | Anti-viral uses of borinic acid complexes | ANACOR PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
| WO-2006007384-A2 | ANTIBIOTICS CONTAINING BORINIC ACID COMPLEXES AND METHODS OF USE | ANACOR PHARMACEUTICALS, INC. (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20060014723-A1 | Anti-parasitic uses of borinic acid complexes | ANACOR PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
| US-20060009422-A1 | Boron-containing compounds and methods of use | ANACOR PHARMACEUTICALS, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005123094-A2 | TREATMENT OR PREVENTION OF SKIN CONDITIONS OR TISSUE CONDITIONS IN ANIMALS USING BORYLOXYPYRIDYLMETHANONES | ANACOR PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005123095-A1 | ANTI-PARASITIC USES OF BORINIC ACID COMPLEXES | ANACOR PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| EP-1581500-A2 | ANTIBIOTICS CONTAINING BORINIC ACID COMPLEXES AND METHODS OF USE | Anacor Pharmaceuticals, Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20050070503-A1 | Antibiotics containing borinic acid complexes and methods of use | ANACOR PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20040224923-A1 | Antibiotics containing borinic acid complexes and methods of use | ANACOR PHARMACEUTICALS, INC. | 2004-11-11 | — | — | US | disclosed |
| WO-2004056322-A2 | ANTIBIOTICS CONTAINING BORINIC ACID COMPLEXES AND METHODS OF USE | ANACOR PHARMACEUTICALS, INC. (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224923-A1 | Antibiotics containing borinic acid complexes and methods of use | BPGM, BROX, TBCA | KCNH2 2124/4885ADRA2B 4247/4885GAA 324/4885 |
| US-20060014723-A1 | Anti-parasitic uses of borinic acid complexes | BPGM, HRH1, HRH3 | KCNH2 1756/4885ADRA2B 3821/4885GAA 325/4885 |
| US-20060009422-A1 | Boron-containing compounds and methods of use | BROX, BTD, PBDC1 | KCNH2 4489/4885ADRA2B 4030/4885GAA 1146/4885 |
| US-20080146803-A1 | ANTIBIOTICS CONTAINING BORINIC ACID COMPLEXES AND METHODS OF USE | BPGM, BROX, TBCA | KCNH2 2124/4885ADRA2B 4247/4885GAA 324/4885 |
| US-20050070503-A1 | Antibiotics containing borinic acid complexes and methods of use | BPGM, BROX, TBCA | KCNH2 2124/4885ADRA2B 4247/4885GAA 324/4885 |
| US-20060019927-A1 | Anti-viral uses of borinic acid complexes | SSB, BPGM, HAVCR2 | KCNH2 2723/4885ADRA2B 4513/4885GAA 230/4885 |
| US-20080293675-A1 | ANTIBIOTICS CONTAINING BORINIC ACID COMPLEXES AND METHODS OF USE | BPGM, BROX, TBCA | KCNH2 2124/4885ADRA2B 4247/4885GAA 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.